Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells $7M in MassARRAYs to Samsung in Diagnostics-Discovery Deal

NEW YORK, June 18 - Sequenom today said it sold "multiple" units of its MassARRAY gene-analysis tools to Korean conglomerate Samsung to help it discover diagnostics.
Terms of the agreement call for Sequenom to receive 50 percent of the rights to any drugs developed from genes discovered by the Samsung Advanced Institute of Technology. The genomic tool shop will also receiv a 5-percent royalty on any diagnostic tests Samsung develops using the technology.

Though no other financial details were released, Reuters reported this morning that Samsung bought $7 million worth of the MassARRAY tools. This figure could not be independently verified.


Click here for more information.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.